These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 826968

  • 21. Propranolol-induced tardive dyskinesia in a patient with akathisia.
    Sandyk R.
    Ann Neurol; 1985 Sep; 18(3):370. PubMed ID: 4051467
    [No Abstract] [Full Text] [Related]

  • 22. Movement disorders induced in monkeys by chronic haloperidol treatment.
    Weiss B, Santelli S, Lusink G.
    Psychopharmacology (Berl); 1977 Aug 16; 53(3):289-93. PubMed ID: 408858
    [Abstract] [Full Text] [Related]

  • 23. Similar effect of estradiol and haloperidol on experimental tardive dyskinesia in monkeys.
    Bédard PJ, Boucher R, Daigle M, Di Paolo T.
    Psychoneuroendocrinology; 1984 Aug 16; 9(4):375-9. PubMed ID: 6514933
    [Abstract] [Full Text] [Related]

  • 24. Reversal of haloperidol-induced orofacial dyskinesia by quercetin, a bioflavonoid.
    Naidu PS, Singh A, Kulkarni SK.
    Psychopharmacology (Berl); 2003 Jun 16; 167(4):418-23. PubMed ID: 12669184
    [Abstract] [Full Text] [Related]

  • 25. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders.
    Ganzini L, Casey DE, Hoffman WF, McCall AL.
    Arch Intern Med; 1993 Jun 28; 153(12):1469-75. PubMed ID: 8512437
    [Abstract] [Full Text] [Related]

  • 26. Behavioural effects of dopamine D-1 and D-2 receptor agonists in monkeys previously treated with haloperidol.
    Lublin H, Gerlach J.
    Eur J Pharmacol; 1988 Aug 24; 153(2-3):239-45. PubMed ID: 3263277
    [Abstract] [Full Text] [Related]

  • 27. Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia.
    Naidu PS, Singh A, Kulkarni SK.
    Neuropharmacology; 2003 Jun 24; 44(8):1100-6. PubMed ID: 12763102
    [Abstract] [Full Text] [Related]

  • 28. U-74500A (lazaroid), a 21-aminosteroid attenuates neuroleptic-induced orofacial dyskinesia.
    Bishnoi M, Chopra K, Kulkarni SK.
    Methods Find Exp Clin Pharmacol; 2007 Nov 24; 29(9):601-5. PubMed ID: 18193111
    [Abstract] [Full Text] [Related]

  • 29. MK-771 antagonizes the enhanced response to apomorphine in rats treated chronically with haloperidol - implications for tardive dyskinesia.
    Yarbrough GG, Faison EP, Antolik EK.
    Neurosci Lett; 1982 Dec 31; 34(3):321-3. PubMed ID: 6819493
    [Abstract] [Full Text] [Related]

  • 30. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
    Bishnoi M, Chopra K, Kulkarni SK.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb 15; 32(2):451-61. PubMed ID: 17988775
    [Abstract] [Full Text] [Related]

  • 31. Exacerbation of tardive dyskinesia by Joseph disease.
    Browne JL, Hart RR.
    J Clin Psychiatry; 1986 Jun 15; 47(6):315-6. PubMed ID: 3711030
    [Abstract] [Full Text] [Related]

  • 32. Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate.
    Hyde TM, Egan MF, Wing LL, Wyatt RJ, Weinberger DR, Kleinman JE.
    Psychopharmacology (Berl); 1995 Mar 15; 118(2):142-9. PubMed ID: 7617800
    [Abstract] [Full Text] [Related]

  • 33. Tardive dyskinesia is associated with altered putamen Akt/GSK-3β signaling in nonhuman primates.
    Hernandez G, Mahmoudi S, Cyr M, Diaz J, Blanchet PJ, Lévesque D.
    Mov Disord; 2019 May 15; 34(5):717-726. PubMed ID: 30675935
    [Abstract] [Full Text] [Related]

  • 34. [Neuroleptic parkinsonism and tardive dyskinesia and methods of pharmacologically correcting these pathologic conditions (review)].
    Arushanian EB.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1985 May 15; 85(2):269-77. PubMed ID: 2858951
    [No Abstract] [Full Text] [Related]

  • 35. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.
    Beasley CM, Dellva MA, Tamura RN, Morgenstern H, Glazer WM, Ferguson K, Tollefson GD.
    Br J Psychiatry; 1999 Jan 15; 174():23-30. PubMed ID: 10211147
    [Abstract] [Full Text] [Related]

  • 36. Effect of neuroleptics and of potential new antipsychotic agents (MJ 13859-1 and MJ 13980-1) on a monkey model of tardive dyskinesia.
    Kovacic B, Ruffing D, Stanley M.
    J Neural Transm; 1986 Jan 15; 65(1):39-49. PubMed ID: 2870130
    [Abstract] [Full Text] [Related]

  • 37. Tardive dyskinesia with low-dose, short-term neuroleptic therapy.
    Stimmel GL.
    Am J Hosp Pharm; 1976 Sep 15; 33(9):961-3. PubMed ID: 984060
    [Abstract] [Full Text] [Related]

  • 38. [The effects of neuroleptics on tardive dyskinesias. A video-controlled, randomized study of chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden].
    Povlsen UJ, Noring U, Meidahl B, Korsgaard S, Waehrens J, Gerlach J.
    Ugeskr Laeger; 1987 Jun 15; 149(25):1682-5. PubMed ID: 3299955
    [No Abstract] [Full Text] [Related]

  • 39. Haloperidol-induced tardive dyskinesia in a child with Gilles de la Tourette's disease.
    Mizrahi EM, Holtzman D, Tharp B.
    Arch Neurol; 1980 Dec 15; 37(12):780. PubMed ID: 6934716
    [Abstract] [Full Text] [Related]

  • 40. Effects of cannabinoid CB1 receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys.
    Madsen MV, Peacock LP, Werge T, Andersen MB, Andreasen JT.
    Neuropharmacology; 2011 Dec 15; 60(2-3):418-22. PubMed ID: 21029743
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.